The challenges facing today’s biotechnology and medical device companies are greater than ever. Companies striving to take promising therapies from the laboratory to the market must protect those therapies from IP, regulatory and reputational risks. Meanwhile, they face steadily increasing pressure on numerous fronts. What new developments are affecting business strategies and bottom lines? Here is a look at eight big topics that life sciences businesses have been thinking about, and how DLA Piper has been covering those stories.